Swedish Orphan Biovitrum AB - Elocta(R) Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia A

STOCKHOLM, May 18, 2017 -- (Healthcare Sales & Marketing Network) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia has approved Elocta® (efmoroctocog alfa), a reco... Biopharmaceuticals, Regulatory Swedish Orphan Biovitrum, Sobi , Elocta , haemophilia A
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news